Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Nat Genet. 2013 Jun 2;45(7):747–755. doi: 10.1038/ng.2650

Figure 6. Genetic and molecular assessments in mice and patients dictate new experimental treatment to overcome CRPC.

Figure 6

(a-d) Apoptosis analysis in human prostate cancer cell line (VCaP) treated with ADT, XIAP inhibitor (embelin), or SRD5A1 inhibitor (dutasteride), as single agent or in combination. Quantifications of PARP cleavage versus total PARP after 2 days of treatment are shown. (e) Weight of VP, DLP, and AP of castration resistant Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre and Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice treated with bicalutamide (Casodex) (n=4/genotype, black bars), bicalutamide plus embelin (n=4/genotype, dark grey bars), or bicalutamide plus embelin plus dutasteride (n=4/genotype, light grey bars) for 4 weeks. Data are presented as mean ± standard deviation.